Christopher K. Mirabelli, PhD
Managing Director, HealthCare Ventures
Dr. Mirabelli joined HealthCare Ventures in 2000 and is a Managing Director at the firm. Dr. Mirabelli was Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999, a company in which HealthCare Ventures was the lead investor. Dr. Mirabelli was also a co-founder of Isis Pharmaceuticals and served with SmithKline and French Laboratories R&D Division. Dr. Mirabelli received his doctorate in molecular pharmacology from Baylor College of Medicine.
Walter Newman, PhD
Chief Scientific Officer
Dr. Newman specializes in scientific evaluations of investment opportunities at HCV, as well as managing, since 2006, the scientific strategy and execution for two of HCV's recent investments as their Chief Scientific Officer. A graduate of Columbia University's undergraduate and graduate programs, with a degree in immunology, Dr Newman was in addition CSO at two HCV portfolio companies (LeukoSite and Critical Therapeutics) prior to joining HCV in 2006. Prior to that, Dr Newman had senior roles in drug discovery at both J&J and Otsuka America Pharmaceuticals, subsequent to an academic career at the Fred Hutchinson Cancer Research Center. He has authored over eighty scientific articles in peer reviewed journals.
Janis Naeve, PhD
Director, Amgen Ventures
Dr. Naeve joined Amgen in 2005 as a Director in the Company's corporate venture capital fund. She directs the fund's investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics which was acquired by Exelixis. Prior to this she was director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly and Bristol Myers-Squibb. Dr. Naeve holds a Ph.D. in Pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.